2017.08.08PDF(128KB)
Announcement of Establishment of New Company
2017.07.18PDF(175KB)
Notification o f the commencement of the Phase III clinical study of HP-3150 in in Japan for "cancer pain" (an algesic transdermal drug containing NSAIDs)
2017.07.07
FY02/2018 Q1 Results Earnings Release Presentation
2017.05.26PDF( 98KB)
Position and Policy Regarding Reduction in the Trading Unit of the Company's Shares
2017.05.18PDF(324KB)
Salonpas Has Been Acknowledged as World's No.1 OTC Topical Analgesics Patch Brand By Euromonitor International